Christiane Margue

University of Luxembourg — LU

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.2kcitations55works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(21), Melanoma and MAPK Pathways(13), Circular RNAs in diseases(8), CAR-T cell therapy research(7), Cytokine Signaling Pathways and Interactions(7)

Publications55 total

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma
Journal of Experimental & Clinical Cancer Research·2025· 2 citedOpen Access
High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma
2025Open Access
High-throughput screening of advanced multicomponent pre-clinical 3D melanoma models identifies potential first-line targeted therapies for NRAS mutant melanoma
EJC Skin Cancer·2025Open Access
Targeting Drug-Tolerant Persister Cells in NRAS-Mutant: A 3D Model-Based Approach for Identifying Novel Therapeutics
EJC Skin Cancer·2025Open Access
Innovative 3D multicomponent melanoma models for in vitro drug screening
EJC Skin Cancer·2025Open Access
Protocol to generate scaffold-free, multicomponent 3D melanoma spheroid models for preclinical drug testing
STAR Protocols·2024· 6 citedOpen Access
TMIC-47. INHIBITION OF MIR-146A-5P DECREASES PROGRESSION OF MELANOMA BRAIN METASTASIS VIA NOTCH PATHWAY DYSREGULATION IN ASTROCYTES
Neuro-Oncology·2023Open Access
Inhibition of extracellular vesicle‐derived miR‐146a‐5p decreases progression of melanoma brain metastasis via Notch pathway dysregulation in astrocytes
Journal of Extracellular Vesicles·2023· 25 citedOpen Access
Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma
Cell Death and Disease·2023· 5 citedOpen Access
A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma
Cancer Gene Therapy·2023· 13 citedOpen Access
Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response
Cell Reports·2023· 14 citedOpen Access
Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Data from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Data from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Stephanie Kreis(42), Demetra Philippidou(27), Iris Behrmann(21), Petr V. Nazarov(14), Martina Schmitt(10), Arnaud Muller(10), Dorothée Nashan(10), Ines Kozar(8), Dirk Moser(8), Laurent Vallar(8), Claude Haan(7), Joanna Wróblewska(7), Tijana Randic(5), Milène Tetsi Nomigni(5), Cristian Angeli(5), Nelly Kieffer(4), Giulia Cesi(4), Nathalie Nicot(4), Eliane Klein(4), Jochen Utikal(3)